ECM
LPCN icon

ExodusPoint Capital Management’s Lipocine LPCN Stock Holding History

ExodusPoint Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-689
Closed -$12K – 2461
2021
Q4 		$12K Sell
689
-644
-48% -$12K ﹤0.01% 2098
2021
Q3 		$25K Buy
+1,333
New +$29.4K ﹤0.01% 2010

Other funds holding LPCN

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

ExodusPoint Capital Management's LPCN Position: Q1 2022 in Review

ExodusPoint Capital Management sold out of Lipocine (LPCN) in Q1 2022, closing a stake of 689 shares — an estimated $12K sold.

ExodusPoint Capital Management first reported a position in LPCN in Q3 2021 and held it in 2 quarters. The position peaked at $25K in Q3 2021. 44 funds tracked by Wall St. Rank hold LPCN as of Q1 2022.

  • ExodusPoint Capital Management reported no remaining Lipocine position as of Q1 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 689 Lipocine shares in Q1 2022, an estimated $12K.
  • ExodusPoint Capital Management first reported a position in Lipocine in Q3 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Lipocine position peaked at $25K in Q3 2021.
  • 44 funds tracked by Wall St. Rank held Lipocine as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.